Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances

Executive Summary

Draft guidelines on interchangeability and statistical considerations due by end of 2017, suggesting long-awaited documents may not see the light of day this year as many had hoped.


Related Content

Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?
Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability
Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action
FDA Biologic Transition Plan Creates 'Dead Zone' For Applications, Sponsors Fear
Biosimilar Labeling: FDA Says Leave Comparability Data Out
Biosimilar Interchangeability Requirements Pushed At Inflectra Review
FDA Sets New Goal For Biosimilar, Drug Promotion Guidances
FDA's Biologics Naming Plan: Industry Wants 'Memorable' Suffixes


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts